We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Candidate Drug Kills CRCs with Mutated Tumor Suppressor Gene

By LabMedica International staff writers
Posted on 04 Nov 2016
Image: The protein produced by the adenomatous polyposis coli (APC) tumor suppressor gene (Photo courtesy of Wikimedia Commons).
Image: The protein produced by the adenomatous polyposis coli (APC) tumor suppressor gene (Photo courtesy of Wikimedia Commons).
A candidate small molecule drug for treatment of colorectal cancer acts by blocking cholesterol biosynthesis in a subset of tumor cells that carry a mutated version of a gene that normally suppresses tumor formation.

Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC) - they are found in more than 80% of colon tumors - and more than 90% of those mutations generate stable truncated gene products.

To identify candidate drugs capable of killing CRC cells with mutated APC, investigators at the University of Texas Southwest Medical Center (Dallas, USA) screened more than 200,000 compounds against a panel of normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein.

They reported in the October 19, 2016, online edition of the journal Science Translational Medicine that a small molecule, TASIN-1 (truncated APC selective inhibitor-1), specifically killed cells with APC truncations but spared normal and cancer cells with wild-type APC. TASIN-1 exerted its cytotoxic effects through inhibition of cholesterol biosynthesis.

In vivo administration of TASIN-1 inhibited tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity.

"Even though such mutations are common in colorectal cancer, there are currently not any therapeutics that directly target these types of mutations, so this represents fresh avenues to approach," said senior author Dr. Jerry W. Shay, professor of cell biology at the University of Texas Southwest Medical Center. "Our latest finding confirms that targeting TASINs is a viable approach. Considering the high prevalence of APC mutations in colon cancer patients, targeting truncated APC could be an effective therapeutic strategy for prevention and intervention of colorectal cancer and could potentially be used as a marker for stratifying patients in future personalized medicine clinical trials."

Related Links:
University of Texas Southwest Medical Center

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Channels

Molecular Diagnostics

view channel
Image: New findings indicate that chimeric RNAs, once viewed as cancer byproducts, can also be part of normal physiology with regulatory functions (Image credit: Adobe Stock)

Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease

Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: Volition’s Nu.Q NETs test detects markers associated with neutrophil extracellular traps, which are released during NETosis and linked to sepsis and other acute and chronic disorders (Image credit: iStock)

Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing

VolitionRx Limited (Henderson, NV, USA), a multinational epigenetics company, has announced a collaboration with Sysmex Corporation (Kobe, Japan), a global leader in in vitro diagnostics, to optimize Volition’s Nu.... Read more
ADLM